NCT00119691View on ClinicalTrials.gov

Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Congestive Heart FailureRenal Insufficiency
Interventions
DRUG

Nesiritide

Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

Scios, Inc.

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT00119691 - Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction | Biotech Hunter | Biotech Hunter